Input or output interoperability
DICOM is explicitly referenced in the described input, output, or workflow.
exact submission · checked 2026-09-01The model card does not establish every supported DICOM object, transfer method, or local interface.
FDA-cleared profile
AI-Rad Companion Prostate MR
Siemens Medical Solutions USA Inc.
Authorized purpose: Assists clinicians in viewing, manipulating, analyzing, and evaluating prostate MR images for US-guided MR-US fusion biopsy support.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Assists clinicians in viewing, manipulating, analyzing, and evaluating prostate MR images for US-guided MR-US fusion biopsy support.
Overview status: Source-reviewed overview
- What does this software do? Authorized purpose: Assists clinicians in viewing, manipulating, analyzing, and evaluating prostate MR images for US-guided MR-US fusion biopsy support.
- Which images or clinical context are in scope? Modality: MRI Anatomy or clinical context: Prostate Input: Prostate MR DICOM images plus clinical PSA input for PSA-density calculation.
- Who uses it? Intended users: Clinicians, including radiologist and urologist workflow participants.
- What does the software produce? Output: Automatic prostate segmentation and volume estimation with manual adjustment, lesion annotation, PSA density, PACS export, and RTStruct export for ultrasound systems.
- What is its most important limitation? Key limitation: Submitted architecture was cloud-based without customer-premise components; it is intended for professionals familiar with MR post-processing and no clinical tests were performed for the modifications.
Clinical takeaway
Clinical role: Assists clinicians in viewing, manipulating, analyzing, and evaluating prostate MR images for US-guided MR-US fusion biopsy support.
Evidence takeaway
Evidence from the reviewed source record: Software unit, system, and integration verification and validation were reported, with no clinical or animal testing for the submitted VA20 modifications.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
- Exact purpose
- Assists clinicians in viewing, manipulating, analyzing, and evaluating prostate MR images for US-guided MR-US fusion biopsy support.
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
- Intended users
- Clinicians, including radiologist and urologist workflow participants.
FDA packet intended-user scope.
- Care setting and population
- Adult
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
- Workflow role
- Post-processing analysis
Conservative normalization of explicit wording in an exact-submission source.
- Required input
- Prostate MR DICOM images plus clinical PSA input for PSA-density calculation.
FDA packet input scope.
- Output and human action
- Automatic prostate segmentation and volume estimation with manual adjustment, lesion annotation, PSA density, PACS export, and RTStruct export for ultrasound systems.
FDA packet output scope.
- Limitations
- Submitted architecture was cloud-based without customer-premise components; it is intended for professionals familiar with MR post-processing and no clinical tests were performed for the modifications.
Exact packet scope, not current deployment assurance.
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Implementation
Questions for IT, informatics, and operations
Use these fields to structure a vendor demo, security review, and implementation estimate.
- Integration
- The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
- Deployment and data flow
- On-cloud
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
- Security and privacy
- Vendor documentation pending
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Training and support
- Vendor documentation pending
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Monitoring and change control
- Vendor documentation pending
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Supported acquisition environment
Supported hardware: Unspecified. Scanner manufacturers: All
exact submission · checked 2026-09-01Confirm currently supported software versions, protocols, and site-specific acquisition configurations.
ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for AI-Rad Companion Prostate MR; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Evidence
Performance evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
- Evidence summary
- Software unit, system, and integration verification and validation were reported, with no clinical or animal testing for the submitted VA20 modifications.
Packet testing description, not clinical-performance evidence.
- Reported sensitivity
- Research pending
This field has not been curated yet.
- Reported specificity
- Research pending
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
AI-Rad Companion Prostate MR regulatory performance study summary
- DesignStand-Alone Performance
- PopulationAdult
- Scopeexact submission
- Tested versionVA30
- IndependenceIndependence not established
K193283
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
- Pricing and total cost
- Vendor documentation pending
No public price or quote for the exact K193283 configuration was established in this review.
- Reimbursement and coding
- Not established in reviewed sources
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
- Postmarket safety review
- The exact-identifier FDA recall query returned no native recall record for K193283. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Buyer worksheet
Open questions to take to the vendor
- Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Verify pricing and total cost: No public price or quote for the exact K193283 configuration was established in this review.
- Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
- Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history
Source ledger
-
FDA K193283: AI-Rad Companion Prostate MR
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary
-
Artificial Intelligence-Enabled Medical Devices
Scope: regulatoryIdentity, modalityContext
-
AI-Rad Companion Prostate MR model card (K193283)
Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
-
PubMed biomedical literature index
Scope: evidenceDiscovery
-
ClinicalTrials.gov study registry
Scope: evidenceDiscovery, studyStatus
-
openFDA Device Recall API
Scope: recallDiscovery, nativeSubmissionMatching
-
openFDA exact recall query for K193283
Scope: postmarketSafety
Research history
-
K193283 FDA decision
Regulatory record
510(k)
-
Source-review record updated
Research record
fda record reviewed
-
Reader overview source-reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Related tools to compare
FDA-cleared K242683
QP-Prostate® CAD
Quibim S.L.
QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning...
- Modality
- MRI
- Anatomy
- Prostate
- Decision
- 2025-03-18
FDA-cleared K241770
Prostate MR AI (VA10A)
Siemens Healthcare GmbH
Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior...
- Modality
- MRI
- Anatomy
- Prostate
- Decision
- 2025-03-05
FDA-cleared K233196
Medihub Prostate
JLK Inc.
Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related...
- Modality
- MRI
- Anatomy
- Prostate
- Decision
- 2024-06-21
FDA-cleared K221624
Avenda Health AI Prostate Cancer Planning Software
Avenda Health, Inc.
Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or...
- Modality
- MRI
- Anatomy
- Prostate
- Decision
- 2022-11-22